Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Ellen Chiniara Sells 3,129 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Ellen Chiniara sold 3,129 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the transaction, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. This trade represents a 5.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kymera Therapeutics Stock Down 1.0 %

Shares of NASDAQ:KYMR opened at $40.52 on Thursday. The firm has a fifty day simple moving average of $44.20 and a two-hundred day simple moving average of $43.92. Kymera Therapeutics, Inc. has a 52 week low of $25.46 and a 52 week high of $53.27. The stock has a market capitalization of $2.62 billion, a P/E ratio of -17.32 and a beta of 2.19.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. During the same quarter last year, the business posted ($0.90) earnings per share. The firm’s revenue was down 20.9% on a year-over-year basis. On average, analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Institutional Trading of Kymera Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC boosted its stake in Kymera Therapeutics by 5.8% during the third quarter. FMR LLC now owns 5,109,141 shares of the company’s stock worth $241,816,000 after buying an additional 282,301 shares during the period. Wellington Management Group LLP boosted its stake in shares of Kymera Therapeutics by 7.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock worth $218,587,000 after purchasing an additional 308,954 shares during the period. Jennison Associates LLC grew its holdings in Kymera Therapeutics by 85.8% during the 3rd quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock valued at $37,754,000 after purchasing an additional 368,394 shares during the last quarter. Eventide Asset Management LLC raised its position in Kymera Therapeutics by 9.9% in the 3rd quarter. Eventide Asset Management LLC now owns 507,902 shares of the company’s stock worth $24,039,000 after purchasing an additional 45,803 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its stake in Kymera Therapeutics by 11.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company’s stock worth $21,458,000 after purchasing an additional 47,507 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms recently issued reports on KYMR. BMO Capital Markets assumed coverage on shares of Kymera Therapeutics in a report on Friday, December 6th. They issued a “market perform” rating and a $55.00 target price for the company. Leerink Partners restated an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. Oppenheimer boosted their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, September 27th. Finally, UBS Group cut their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $55.38.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.